Sarepta Therapeutics, based in the US, is undergoing significant turmoil following the disclosure that three patients have passed away this year while receiving its gene therapies. These fatalities led the US Food and Drug Administration (FDA) to request that Sarepta cease shipments of Elevidys (delandistrogene moxeparvovec), which is aimed at treating Duchenne muscular dystrophy (DMD). […]
Read More